Book a Meeting

Non-fucosylated Anti-Human IL-23 p19 (Risankizumab) Therapeutic Antibody (CAT#: BioBet-054ZP) Datasheet

Target
IL-23 p19
Isotype
IgG1
Description
ADCC-enhanced Risankizumab is a non-fucosylated anti-IL-23 p19 therapeutic biobetter antibody.
Indication
Plaque psoriasis
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IL-23 p19 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IL-23 p19
Full Name
IL-23 p19
Alternative Names
IL-23 p19
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with IL23A include Multiple Sclerosis and Inflammatory Bowel Disease.
Related Pathways
Its related pathways are Tuberculosis and PEDF Induced Signaling.
Function
Combined with IL12B to form IL-23 interleukin, which is a heterodimeric cytokine that plays a role in innate immunity and adaptive immunity. IL-23 and IL-17 may constitute an acute response to surrounding tissue infection. IL-23 binds to the heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory instead of naive T cells, and promotes the production of pro-inflammatory cytokines. IL-23 induces autoimmune inflammation, so it may be the cause of autoimmune inflammatory diseases and may be important for tumor occurrence.
Post-translational modifications
No Post-translational modifications
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
Risankizumab
Host
Humanized
Species Reactivity
Human
Description
Risankizumab is a humanized monoclonal antibody that targets interleukin 23A (IL-23A). Risankizumab was used for the treatment of moderate to severe plaque psoriasis.
Indication
Moderate plaque-type psoriasis
Severe plaque-type psoriasis

Moderate plaque-type psoriasis
Severe plaque-type psoriasis

Related Products

Non-fucosylated Anti-Human IL-23 p19 (Guselkumab) Therapeutic Antibody (CAT#: BioBet-046ZP)
BetterBet™ Anti-IL-23 p19 On-Target Antibody (CAT#: AES-0622-ZP932)
Highly Galactosylated Anti-IL-23 p19 (Tildrakizumab) Antibody (CAT#: BioBet-GA-052ZP)
BetterBet™ Anti-IL-23 p19 FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP604)
Highly Galactosylated Anti-IL-23 p19 (Guselkumab) Antibody (CAT#: BioBet-GA-046ZP)
Highly Galactosylated Anti-IL-23 p19 (Risankizumab) Antibody (CAT#: BioBet-GA-054ZP)
BetterBet™ Anti-IL-23 p19 Half-Life Extended Antibody (CAT#: AES-0622-ZP1260)
BetterBet™ Anti-IL-23 p19 Recycling Antibody (CAT#: AES-0622-ZP276)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.